ISRCTN11842403已完成1 期
Peptide vaccination against cytomegalovirus (CMV) in CMV seronegative end-stage renal disease patients
Renal Center Heidelberg0 个研究点目标入组 10 人开始时间: 2017年4月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
2021 Results article in https://doi.org/10.3390/vaccines9020133 (added 06/06/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18 years and over
- •2. End-stage renal disease
- •3. CMV IgG seronegative
- •4. HLA-A2 expression positivity
- •5. Liver function tests below the threefold of the normal upper values
- •6. No active infection
- •7. Expected compliance
- •8. Provision of written informed consent
排除标准
- •1. Prednisolone therapy >25 mg/d
- •2. Planned vaccination of other indication within the study period
研究者
相似试验
已完成
1 期
Cytomegalovirus Vaccine in Healthy ParticipantsPrecancerous/Nonmalignant ConditionNCT00712634City of Hope Medical Center46
已完成
1 期
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to TherapyCancerNCT00509691University of Louisville20
招募中
2 期
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaHigh Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent MedulloblastomaNCT05096481Nationwide Children's Hospital120
已完成
2 期
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)Cytomegalovirus (CMV) InfectionsNCT03486834Merck Sharp & Dohme LLC2,200
已完成
1 期
Vaccine Therapy in Preventing Cytomegalovirus in Healthy ParticipantsNonneoplastic ConditionNCT00722839City of Hope Medical Center68